Merck & Co. Eyes Neuroscience Advancement With US FDA’s New Receptivity To Biomarkers

 
• By Brenda Sandburg
  
Neuroscience
Merck & Co. notes changing regulatory landscape on use of biomarkers in neuroscience drug development • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D